chang alexion fve result
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
methodolog valu compani
maintain fair valu estim alexion
pharmaceut incorpor fourth-quart result
guidanc model full-year top-lin result
slightli expect off-set
higher-than-anticip oper expens driven
on-going pivot trial continu ramp alexion
portfolio encourag see strong underli
volum demand drive soliri metabol franchis sale
respons manag project slightli
lower estim soliri growth given higher-
than-expect impact on-going pivot trial evalu
alexion next-gener product
competitor molecul soliri sale believ alexion
accord estim
growth fourth quarter thank strong underli
demand rare blood diseas paroxysm nocturn
hemoglobinuria atyp hemolyt urem syndrom
compani lead drug also receiv approv
subtyp myasthenia gravi anoth blood disord
estim could provid elig patient
unit state european union label expans
limit impact fourth-quart sale launch
new indic help off-set headwind
on-going trial enrol million impact
sale anticip effect trial enrol
temporari pressur soliri sale
bear fundament growth drug
price pressur project neg impact
expect new normal compani
believ grow patient demand off-set
phenomenon
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
special develop market drug
life-threaten medic condit blockbust product soliri
approv therapi paroxysm nocturn hemoglobinuria
atyp hemolyt urem syndrom two ultra-rar blood disord
recent approv gener myasthenia gravi strensiq kanuma
target ultra-rar metabol diseas alexion pipelin target area
high unmet need complement-medi disord
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
sale rare metabol diseas drug strensiq kanuma
increas quarter quarter respect
fourth-quart revenu aid time tender
order extent strong patient growth main
driver model oper expens toward
midpoint manag guidanc margin step
prior estim posit pivot result
alexion conveni next-gen soliri pnh patient
infus everi eight week versu everi two week
soliri expect second quarter follow
eu japan submiss second half year
expect next-gen product allow
firm better protect complement franchis pipelin
competit may slightli aid better market penetr
rate part anticip new drug
replac soliri sale data alexion next-gen
subcutan trial expect trial initi second
half year expect entrench
compani moat posit readout soliri
relaps neuromyel optica spectrum disord
similar symptom multipl sclerosi provid anoth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
